Clinical trial
A Phase II Study to Assess the Hemodynamic Effects of Istaroxime, a Novel Lusinotropic Agent, in Patients Hospitalized With Worsening Heart Failure and a Reduced Left Ventricular Systolic Function
NCT00616161 is registered in ClinicalTrials.gov with sigma-tau i.f.r. S.p.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study to Assess the Hemodynamic Effects of Istaroxime, a Novel Lusinotropic Agent, in Patients Hospitalized With Worsening Heart Failure and a Reduced Left Ventricular Systolic Function
- Lead sponsor
- sigma-tau i.f.r. S.p.A.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2006
- Completion date
- August 31, 2007
- Enrollment
- 120 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.